Aurimi Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 5

Aurimi Therapeutics General Information

Description

Developer of a biotechnology platform designed to build drug molecules for the specific blockade of autoimmune disease-associated antibodies. The company's platform screens compounds for optimal docking within human leukocyte antigens, together with rational drug design and bioassays to build targeted therapeutic candidates, enabling patients and health professionals to detect early signs across autoimmune diseases.

Contact Information

Formerly Known As
IM Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 299 Washington Street
  • Suite A
  • Woburn, MA 01801
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 299 Washington Street
  • Suite A
  • Woburn, MA 01801
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurimi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator Completed Generating Revenue
5. Later Stage VC (Series A) 30-Oct-2020 Completed Generating Revenue
4. Early Stage VC (Series A) 09-Oct-2019 Completed Startup
3. Angel (individual) 03-Aug-2016 Completed Startup
2. Angel (individual) 30-Jun-2015 $500K $500K Completed Startup
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Aurimi Therapeutics’s complete valuation and funding history, request access »

Aurimi Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform designed to build drug molecules for the specific blockade of autoimmune disease-a
Drug Discovery
Woburn, MA
4 As of 2026

Brisbane, CA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aurimi Therapeutics Competitors (47)

One of Aurimi Therapeutics’s 47 competitors is Second Genome, a Formerly VC-backed company based in Brisbane, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Formerly VC-backed Brisbane, CA
Enterome Venture Capital-Backed Paris, France
AnTolRx Formerly VC-backed Cambridge, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
CSL Behring Corporation King Of Prussia, PA
You’re viewing 5 of 47 competitors. Get the full list »

Aurimi Therapeutics Patents

Aurimi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023287740-A1 Compounds and methods for treating autoimmune disorders by targeting hla-dq2 Inactive 16-Jul-2021
EP-4267123-A1 Methods for producing d-?-methyldopa Pending 23-Dec-2020
EP-4267123-A4 Methods for producing d-?-methyldopa Pending 23-Dec-2020
US-20220194893-A1 Methods for producing d-alpha-methyldopa Active 23-Dec-2020
US-11702383-B2 Methods for producing d-α-methyldopa Active 23-Dec-2020 C07C227/02
To view Aurimi Therapeutics’s complete patent history, request access »

Aurimi Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aurimi Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
CU Healthcare Innovation Fund Corporate Venture Capital Minority
Morningside Group Venture Capital Minority
T1D Fund Venture Capital Minority
University of Florida University
C2I Accelerator Accelerator/Incubator
To view Aurimi Therapeutics’s complete investors history, request access »

Aurimi Therapeutics FAQs

  • When was Aurimi Therapeutics founded?

    Aurimi Therapeutics was founded in 2015.

  • Where is Aurimi Therapeutics headquartered?

    Aurimi Therapeutics is headquartered in Woburn, MA.

  • What is the size of Aurimi Therapeutics?

    Aurimi Therapeutics has 4 total employees.

  • What industry is Aurimi Therapeutics in?

    Aurimi Therapeutics’s primary industry is Drug Discovery.

  • Is Aurimi Therapeutics a private or public company?

    Aurimi Therapeutics is a Private company.

  • What is Aurimi Therapeutics’s current revenue?

    The current revenue for Aurimi Therapeutics is .

  • How much funding has Aurimi Therapeutics raised over time?

    Aurimi Therapeutics has raised $17.9M.

  • Who are Aurimi Therapeutics’s investors?

    CU Healthcare Innovation Fund, Morningside Group, T1D Fund, University of Florida, and C2I Accelerator have invested in Aurimi Therapeutics.

  • Who are Aurimi Therapeutics’s competitors?

    Second Genome, Enterome, AnTolRx, Adaptimmune Therapeutics, and CSL Behring are some of the 47 competitors of Aurimi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process